Elacyt

Vladimir Beljanski

doi:10.1016/B978-008055232-3.64090-5

Elacyt

Vladimir Beljanski

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Elacyt is a cytotoxic agent being tested as a treatment for haematologic cancers and solid tumors. To enhance cellular drug uptake, lipophilic analogs (5'-elaidic acid esters) of cytarabine and gemcitabine were synthesized. Elacyt (5'-. O-(trans-9'-octadecenoyl)-1-β-d-arabinofuranosyl cytosine) has a longer cellular retention and a different effect on DNA and RNA synthesis than cytarabine. Elacyt has distinct antitumor activity in various solid tumour xenografts in which cytarabine is inactive. In phase I trials, elacyt displayed a favorable safety profile. Activity has been demonstrated in melanoma, NSCLC, and lung cancer refractory to gemcitabine treatment (Breistøl, 1999) ... © 2008

Original language	English
Title of host publication	xPharm
Subtitle of host publication	The Comprehensive Pharmacology Reference
Editors	S.J. Enna, David B. Bylund
Publisher	Elsevier Inc.
Pages	1-4
Number of pages	4
ISBN (Print)	9780080552323
DOIs	https://doi.org/10.1016/B978-008055232-3.64090-5
State	Published - 2008
Externally published	Yes

ASJC Scopus Subject Areas

General Pharmacology, Toxicology and Pharmaceutics

Disciplines

Medicine and Health Sciences

Access to Document

10.1016/B978-008055232-3.64090-5

Cite this

@inbook{7e974d93a16c43f08281dd063eb23bb6,

title = "Elacyt",

abstract = "Elacyt is a cytotoxic agent being tested as a treatment for haematologic cancers and solid tumors. To enhance cellular drug uptake, lipophilic analogs (5'-elaidic acid esters) of cytarabine and gemcitabine were synthesized. Elacyt (5'-. O-(trans-9'-octadecenoyl)-1-β-d-arabinofuranosyl cytosine) has a longer cellular retention and a different effect on DNA and RNA synthesis than cytarabine. Elacyt has distinct antitumor activity in various solid tumour xenografts in which cytarabine is inactive. In phase I trials, elacyt displayed a favorable safety profile. Activity has been demonstrated in melanoma, NSCLC, and lung cancer refractory to gemcitabine treatment (Breist{\o}l, 1999) ... {\textcopyright} 2008",

author = "Vladimir Beljanski",

year = "2008",

doi = "10.1016/B978-008055232-3.64090-5",

language = "English",

isbn = "9780080552323",

pages = "1--4",

editor = "S.J. Enna and Bylund, \{David B.\}",

booktitle = "xPharm",

publisher = "Elsevier Inc.",

address = "United States",

}

TY - CHAP

T1 - Elacyt

AU - Beljanski, Vladimir

PY - 2008

Y1 - 2008

N2 - Elacyt is a cytotoxic agent being tested as a treatment for haematologic cancers and solid tumors. To enhance cellular drug uptake, lipophilic analogs (5'-elaidic acid esters) of cytarabine and gemcitabine were synthesized. Elacyt (5'-. O-(trans-9'-octadecenoyl)-1-β-d-arabinofuranosyl cytosine) has a longer cellular retention and a different effect on DNA and RNA synthesis than cytarabine. Elacyt has distinct antitumor activity in various solid tumour xenografts in which cytarabine is inactive. In phase I trials, elacyt displayed a favorable safety profile. Activity has been demonstrated in melanoma, NSCLC, and lung cancer refractory to gemcitabine treatment (Breistøl, 1999) ... © 2008

AB - Elacyt is a cytotoxic agent being tested as a treatment for haematologic cancers and solid tumors. To enhance cellular drug uptake, lipophilic analogs (5'-elaidic acid esters) of cytarabine and gemcitabine were synthesized. Elacyt (5'-. O-(trans-9'-octadecenoyl)-1-β-d-arabinofuranosyl cytosine) has a longer cellular retention and a different effect on DNA and RNA synthesis than cytarabine. Elacyt has distinct antitumor activity in various solid tumour xenografts in which cytarabine is inactive. In phase I trials, elacyt displayed a favorable safety profile. Activity has been demonstrated in melanoma, NSCLC, and lung cancer refractory to gemcitabine treatment (Breistøl, 1999) ... © 2008

UR - https://www.scopus.com/pages/publications/84884067766

UR - https://www.scopus.com/pages/publications/84884067766#tab=citedBy

U2 - 10.1016/B978-008055232-3.64090-5

DO - 10.1016/B978-008055232-3.64090-5

M3 - Chapter

AN - SCOPUS:84884067766

SN - 9780080552323

SP - 1

EP - 4

BT - xPharm

A2 - Enna, S.J.

A2 - Bylund, David B.

PB - Elsevier Inc.

ER -

Elacyt

Abstract

ASJC Scopus Subject Areas

Disciplines

Access to Document

Other files and links

Fingerprint

Cite this